KR101303131B1 - Composition for applying on skin containing sericite - Google Patents
Composition for applying on skin containing sericite Download PDFInfo
- Publication number
- KR101303131B1 KR101303131B1 KR1020110036554A KR20110036554A KR101303131B1 KR 101303131 B1 KR101303131 B1 KR 101303131B1 KR 1020110036554 A KR1020110036554 A KR 1020110036554A KR 20110036554 A KR20110036554 A KR 20110036554A KR 101303131 B1 KR101303131 B1 KR 101303131B1
- Authority
- KR
- South Korea
- Prior art keywords
- phase
- purified water
- extract
- composition
- confirming
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 239000010445 mica Substances 0.000 claims abstract description 9
- 229910052618 mica group Inorganic materials 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 25
- 239000000284 extract Substances 0.000 claims description 24
- 239000008213 purified water Substances 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 19
- 229910052732 germanium Inorganic materials 0.000 claims description 18
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 claims description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 17
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 17
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 17
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 16
- 238000004090 dissolution Methods 0.000 claims description 16
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 14
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 12
- 238000000855 fermentation Methods 0.000 claims description 12
- 230000004151 fermentation Effects 0.000 claims description 12
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 12
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 11
- 229940041616 menthol Drugs 0.000 claims description 11
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 9
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 9
- 229920002774 Maltodextrin Polymers 0.000 claims description 9
- 239000005913 Maltodextrin Substances 0.000 claims description 9
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 9
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 9
- GUBGYTABKSRVRQ-ASMJPISFSA-N alpha-maltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-ASMJPISFSA-N 0.000 claims description 9
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 9
- 235000011187 glycerol Nutrition 0.000 claims description 9
- 229940035034 maltodextrin Drugs 0.000 claims description 9
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 claims description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 8
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 8
- 229920001353 Dextrin Polymers 0.000 claims description 8
- 239000004375 Dextrin Substances 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 241000186660 Lactobacillus Species 0.000 claims description 8
- 229920002125 Sokalan® Polymers 0.000 claims description 8
- 229960000458 allantoin Drugs 0.000 claims description 8
- 229960003237 betaine Drugs 0.000 claims description 8
- 229960002079 calcium pantothenate Drugs 0.000 claims description 8
- 229960001631 carbomer Drugs 0.000 claims description 8
- 239000003086 colorant Substances 0.000 claims description 8
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 8
- 235000019425 dextrin Nutrition 0.000 claims description 8
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 229940039696 lactobacillus Drugs 0.000 claims description 8
- 229940069445 licorice extract Drugs 0.000 claims description 8
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 8
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 8
- 229960002216 methylparaben Drugs 0.000 claims description 8
- 229960003966 nicotinamide Drugs 0.000 claims description 8
- 235000005152 nicotinamide Nutrition 0.000 claims description 8
- 239000011570 nicotinamide Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000000377 silicon dioxide Substances 0.000 claims description 8
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 claims description 8
- 229940011671 vitamin b6 Drugs 0.000 claims description 8
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 7
- 244000068988 Glycine max Species 0.000 claims description 7
- 235000010469 Glycine max Nutrition 0.000 claims description 7
- 239000001140 aloe barbadensis leaf extract Substances 0.000 claims description 7
- 229940069638 aloe vera leaf extract Drugs 0.000 claims description 7
- 235000014066 European mistletoe Nutrition 0.000 claims description 6
- 235000012300 Rhipsalis cassutha Nutrition 0.000 claims description 6
- 239000004359 castor oil Substances 0.000 claims description 6
- 235000019438 castor oil Nutrition 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 6
- -1 licorice extract Chemical compound 0.000 claims description 6
- 229910052626 biotite Inorganic materials 0.000 claims description 5
- 229960001031 glucose Drugs 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229960004063 propylene glycol Drugs 0.000 claims description 4
- 235000008160 pyridoxine Nutrition 0.000 claims description 4
- 239000011677 pyridoxine Substances 0.000 claims description 4
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims 2
- 244000152640 Rhipsalis cassutha Species 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 17
- 230000017531 blood circulation Effects 0.000 description 14
- 230000003750 conditioning effect Effects 0.000 description 13
- 210000003205 muscle Anatomy 0.000 description 11
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 238000005259 measurement Methods 0.000 description 6
- 241000221012 Viscum Species 0.000 description 5
- 150000001450 anions Chemical class 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- 239000004909 Moisturizer Substances 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 230000001333 moisturizer Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 4
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004332 deodorization Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011265 semifinished product Substances 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 241000931705 Cicada Species 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000014104 aloe vera supplement Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 235000012745 brilliant blue FCF Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- OGGXGZAMXPVRFZ-UHFFFAOYSA-N dimethylarsinic acid Chemical compound C[As](C)(O)=O OGGXGZAMXPVRFZ-UHFFFAOYSA-N 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000032630 lymph circulation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000012736 patent blue V Nutrition 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 210000002321 radial artery Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000007371 visceral function Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 피부 도포용 조성물에 관한 것으로, 특히 나노 크기의 견운모를 함유하여 흡수가 빠르고 인체에 유익한 피부 도포용 조성물을 제공한다.The present invention relates to a composition for skin application, and particularly, provides a composition for skin application containing nano-sized mica and its absorption is fast and beneficial to the human body.
Description
본 발명은 피부 도포용 조성물에 관한 것으로, 특히 견운모(sericite)를 함유하여 시원함, 편안함, 진정효과를 나타내는 피부 도포용 조성물 및 이의 제조방법에 관한 것이다.
The present invention relates to a composition for applying a skin, and more particularly to a composition for applying a skin and a method for preparing the same, which contains cool sericite and shows a cool, comfortable and soothing effect.
마사지는 주로 손을 사용하여 직접 피부에 일정한 방법으로 역학적 자극을 줌으로써 생체반응을 일으키게 하여 신체의 변조를 바로 잡아 병을 치료하고 건강을 증진시키는 일종의 수기시술이다.Massage is a kind of manual procedure that treats disease and improves health by correcting the body's modulation by giving a mechanical response to the skin directly by using mechanical hand in a certain way.
마사지에 의해 혈액이나 림프의 순환을 촉진하고 신진대사를 왕성하게 하여 조직의 영양을 높여 주며, 노폐물을 배설하도록 하고 저항력을 증강시켜 준다. 이 촉압자극은 신경을 자극하여 진통적으로 작용하기 때문에 마비된 신경의 회복을 촉진하고, 내장기능의 변조를 바로잡는 효과가 있다.Massage promotes blood circulation and lymph circulation, stimulates metabolism, enhances tissue nutrition, excretes waste and strengthens resistance. This stimulating stimulus stimulates nerves to work painfully, thus facilitating the recovery of paralyzed nerves and correcting the modulation of visceral function.
마사지가 치료법으로 체계화된 것은 16세기 후반~19세기 말에 유럽에서 비롯되었으며, 엄밀한 의미에서 의료상의 마사지는 이학요법사가 의사의 지시나 처방에 따라 기능 훈련과 함께 사용하여 행하는 기술로서 현대의학에서 순환생리학(의 원리를 기초로 하여 전신에 퍼진 혈액을 효율적으로 심장에 되돌려 보내기 위한 구심성 치료법이다.Massage was organized as a treatment in Europe in the late 16th and late 19th centuries.In strict sense, medical massage is a technique used by a therapist in combination with functional training according to a doctor's instruction or prescription. Based on the principles of physiology, it is a centripetal treatment to efficiently return the blood spread throughout the body to the heart.
마사지를 할 때는 아연화, 녹말, 향료 등을 섞은 마사지 파우더나 유지, 글리세린, 올리브유, 크림 같은 마사지 오일을 사용한다.
When you massage, use massage powders that contain zinc, starch, and flavors, or massage oils such as oils, glycerin, olive oil, and cream.
본 발명의 목적은 종래의 마사지 조성물에 비하여 흡수가 빠르고 인체에 더욱 유익한 피부 도포용 조성물 및 이의 제조방법을 제공하는 것이다.
It is an object of the present invention to provide a composition for applying skin and a method for producing the same, which is faster than absorption and more beneficial to the human body than conventional massage compositions.
본 발명은 상기 목적을 달성하기 위하여, 견운모를 포함하는 피부 도포용 조성물을 제공한다.The present invention, in order to achieve the above object, provides a composition for applying the skin comprising the mica.
본 발명에서 견운모는 게르마늄을 포함하여 인체에 유익한 각종 효과를 얻을 수 있고, 나노 크기로 이루어짐으로써 피부에 빠르고 효과적으로 침투할 수 있다.In the present invention, the biotite can obtain various beneficial effects on the human body, including germanium, and can be quickly and effectively penetrate the skin by being made of nano size.
본 발명의 조성물은 감초 추출물, 알로에 베라 잎 추출물, 효모/겨우살이 발효 추출물, 락토바실러스/콩 발효 추출물, 효모/모근 발효 추출물, 정제수, 에탄올, 프로필렌 글리콜, 멘톨, 부틸렌 글리콜, 글리세린, 카보머, 트리에탄올아민, 베타인, 알란토인, 메틸 파라벤, 글루코오스, 덱스트린, 나이아신 아미드, 칼슘 판토테네이트, 소듐 아스코빌 포스페이트, 토코페릴 아세테이트, 피리독신 에이치씨엘, 디소듐 이디티에이, 말토덱스트린, 아밀로덱스트린, 실리카 중에서 선택되는 1종 이상을 추가로 포함할 수 있다.The composition of the present invention is licorice extract, aloe vera leaf extract, yeast / mistletoe fermentation extract, lactobacillus / soybean fermentation extract, yeast / hair root fermentation extract, purified water, ethanol, propylene glycol, menthol, butylene glycol, glycerin, carbomer, Among triethanolamine, betaine, allantoin, methyl paraben, glucose, dextrin, niacin amide, calcium pantothenate, sodium ascorbyl phosphate, tocopheryl acetate, pyridoxine HCI, disodium idieti, maltodextrin, amylodextrin, silica It may further comprise one or more selected.
또한, 본 발명은 정제수, 나이아신 아미드, 아밀로덱스트린, 칼슘 판토테네이트, 말토덱스트린, 소듐 아스코빌 포스페이트, 토코페릴 아세테이트, 피리독신 에이치씨엘, 실리카, 베타인, 감초 추출물, 글루코오스, 덱스트린, 디소듐 이디티에이, 알란토인을 포함하는 A상을 메인 가마에 투입하고 교반하는 단계; A상의 용해를 확인한 후, 미리 풀어둔 정제수와 카보머를 포함하는 B상을 메인 가마에 투입하고 교반하는 단계; B상의 완전 용해를 확인한 후, 미리 희석시켜 둔 정제수와 트리에탄올아민을 포함하는 C상을 메인 가마에 투입하고 교반하는 단계; 완전 용해를 확인한 후, 별도 용기에 실온의 정제수와 견운모 파우더를 포함하는 D상을 투입하고 교반하여 완전 분산시킨 후, 이를 바로 메인 가마에 교반하면서 투입하는 단계; 메인가마의 분산을 확인 후, 미리 가용화시킨 프로필렌 글리콜, 멘톨, 메틸 파라벤, 피이지-60 하이드로제네이티드 캐스터 오일을 포함하는 E상을 투입한 후, 에탄올을 포함하는 F상으로 헹구어 마저 투입하는 단계; 및 용해를 확인한 후, 착색제를 포함하는 G상과, 알로에 베라 잎 추출물, 효모/겨우살이 발효 추출물, 락토바실러스/콩 발효 추출물, 효모/모근 발효 추출물, 부틸렌 글리콜, 글리세린을 포함하는 H상을 순서대로 투입하고 교반하는 단계를 포함하는 피부 도포용 조성물의 제조방법을 제공한다.
In addition, the present invention is purified water, niacin amide, amylodextrin, calcium pantothenate, maltodextrin, sodium ascorbyl phosphate, tocopheryl acetate, pyridoxine HCl, silica, betaine, licorice extract, glucose, dextrin, disodium idi Putting A and A phase containing allantoin into a main kiln and stirring; After confirming the dissolution of phase A, adding the purified water and carbomer phase B previously released into the main kiln and stirring; After confirming complete dissolution of phase B, adding phase C containing purified water and triethanolamine previously diluted to the main kiln and stirring; After confirming complete dissolution, the phase D containing purified water and mica powder at room temperature in a separate container and stirred to completely disperse, and then immediately adding it to the main kiln while stirring; After confirming the dispersion of the main kiln, injecting the E phase containing propylene glycol, menthol, methyl paraben, PIG-60 hydrogenated castor oil solubilized in advance, and then rinsing with an F phase containing ethanol and then adding ; And after confirming the dissolution, the G phase containing a colorant, and the H phase comprising aloe vera leaf extract, yeast / mistletoe fermentation extract, lactobacillus / soybean fermentation extract, yeast / hair root fermentation extract, butylene glycol, glycerin It provides a method for producing a composition for applying the skin comprising the step of adding and stirring as it is.
본 발명에 따른 피부 도포용 조성물은 견운모에서 추출한 게르마늄과 수십여 가지의 성분으로 제조한 나노 겔(게르마늄 견운모)을 함유함으로써, 피부 부위에 빠르게 침투하여 탁월한 효과를 직접 피부로 느낄 수 있다.The composition for skin application according to the present invention contains germanium extracted from the mica and the nanogel (germanium mica) made of dozens of components, so that it can quickly penetrate into the skin area and feel the excellent effect directly to the skin.
본 발명에 따른 피부 도포용 조성물은 신체의 근육과 관절이 형성된 부위에 빠른 흡수작용을 나타내고, 나노 겔과 멘톨 작용은 근육, 관절, 어깨 결림, 목, 다리 관절, 허리 통증, 손, 발 저림에 마사지하면 혈액순환과 뭉친 근육에 효과적이며, 스포츠 선수들의 운동 전과 후에 뭉친 근육에 효과적이고, 견운모에 다량 함유되어 있는 음이온과 원적외선은 독소 배출과 항균, 항독, 정화 작용으로 시원함을 느끼게 한다.
The composition for applying the skin according to the present invention exhibits rapid absorption in the areas where muscles and joints are formed in the body, and the nanogels and menthol action are used for muscles, joints, shoulder stiffness, neck, leg joints, back pain, hand and foot numbness. Massage is effective for blood circulation and clumped muscles. It is effective for clumped muscles before and after sports of athletes. Anion and far-infrared rays contained in large amounts of stiff hair make it feel cool by toxin discharge, antibacterial, antitoxicity and purification.
이하, 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
본 발명 견운모를 포함하는 피부 도포용 조성물에 관한 것이다.The present invention relates to a composition for skin application comprising the mica.
본 발명에서 견운모는 게르마늄을 포함하여 인체에 유용한 작용을 하며, 나노 크기로 이루어짐으로써 피부에 빠르고 효과적으로 침투할 수 있다.In the present invention, the biotite has a useful effect on the human body, including germanium, and can be quickly and effectively penetrates the skin by being made of nano size.
신비의 약리작용을 하는 게르마늄의 인체에 대한 작용원리를 살펴보면, 인체 각 기관, 각 부분은 각각 고유의 응집체로서 기능을 하고 있기 때문에, 각 부분은 정해진 전위가 있고 그 전위가 뒤틀린 것이 질병이며, 어떤 이유로 과잉 축적되면 그곳에 전위가 뒤틀리게 되고 통증이 오는데, 이런 곳에 게르마늄이 침투하게 되면 방전을 시키기 때문에 통증이 사라지게 되는 것을 볼 수 있다.If we look at the working principle of germanium, which acts as a mysterious pharmacology on the human body, since each organ and each part of the human body functions as its own aggregates, each part has a predetermined potential, and the potential is distorted. For this reason, if the accumulation is overwhelmed with dislocations and pain comes, when the germanium penetrates the place, it can be seen that the pain disappears because it discharges.
순도가 높은 유기 게르마늄은 복용 후 인체 내에서 각종 임무를 마친 후 약 20-30시간 안에 인체 내에 있는 암세포, 독소, 오염물질, 중금속 등을 붙들고 축적되는 것 없이 소변을 통해 인체에서 완전히 빠져나가므로 전혀 독성이 남지 않아 매우 안전하다(Asai Germanium Research Institute, Tokyo, Japan).High-purity organic germanium completely escapes from the human body through urine without holding and accumulating cancer cells, toxins, pollutants, and heavy metals in the human body within about 20-30 hours after taking various tasks in the human body after taking them. It is very safe with no toxicity left (Asai Germanium Research Institute, Tokyo, Japan).
게르마늄은 많은 사람이 고통받고 있는 바이러스성의 만성피로 증후군(Chronic Epstein-Barr Virus Syndrome)의 증상을 약화시키고 완화시켜 준다(Use of Organic Germanium in Chronic Epstein-Barr virus Syndrome, Journal of Orthomolecular Medicine, 1989).Germanium attenuates and alleviates the symptoms of the Chronic Epstein-Barr Virus Syndrome, which many suffer from (Use of Organic Germanium in Chronic Epstein-Barr virus Syndrome, Journal of Orthomolecular Medicine, 1989).
유기 게르마늄은 경구 투여와 주사에서 똑같이 모르핀과 같은 강력한 진통작용을 보여주며, 게르마늄을 복용 또는 투여하면 인체 내에서 엔도르핀의 생산을 늘리고, 인체의 각 감각기관들이 진통작용을 늘리는 것으로 나타났다(Journal of Pharmacological Dynamics, 1983: 814-820).Organic germanium has the same potent analgesic effect as morphine in oral administration and injection, and taking or administering germanium increases the production of endorphin in the human body and increases the analgesic effect of each sensory organ of the human body (Journal of Pharmacological Dynamics, 1983: 814-820.
견운모의 함량은 조성물 전체 중량에 대하여 0.01 내지 5 중량%가 적절하다.The content of the mica is suitably 0.01 to 5% by weight based on the total weight of the composition.
본 발명의 조성물은 견운모 이외에 용제, 보습제, 스킨 컨디셔닝제, 점증제, pH 조절제, 계면활성제, 방부제, 산화방지제, 금속이온 봉쇄제, 팽윤제, 착색제 등을 포함할 수 있다.The composition of the present invention may include solvents, humectants, skin conditioners, thickeners, pH adjusters, surfactants, preservatives, antioxidants, metal ion sequestrants, swelling agents, coloring agents, and the like, in addition to the villus.
용제로는 정제수와 같은 물, 에탄올과 같은 알코올을 사용할 수 있다. 용제의 함량은 조성물 전체 중량에 대하여 70 내지 90 중량%가 적절하다.As the solvent, water such as purified water or alcohol such as ethanol may be used. The content of the solvent is suitably 70 to 90% by weight based on the total weight of the composition.
보습제로는 프로필렌 글리콜, 부틸렌 글리콜, 글리세린, 글루코오스 등을 사용할 수 있다. 보습제의 함량은 조성물 전체 중량에 대하여 5 내지 15 중량%가 적절하다.As the humectant, propylene glycol, butylene glycol, glycerin, glucose and the like can be used. The content of the humectant is suitably 5 to 15% by weight based on the total weight of the composition.
스킨 컨디셔닝제(skin conditioning agent)로는 멘톨(menthol), 베타인(betaine), 알란토인(allantoin), 감초 추출물, 알로에 베라(aloe vera) 잎 추출물, 효모/겨우살이 발효 추출물, 락토바실러스(lactobacillus)/콩 발효 추출물, 효모/모근 발효 추출물, 나이아신아미드(niacinamide), 칼슘 판토테네이트(calcium pantothenate), 피리독신 에이치씨엘(pyridoxine HCl), 말토덱스트린(maltodextrin) 등을 사용할 수 있다. 스킨 컨디셔닝제의 함량은 조성물 전체 중량에 대하여 1 내지 10 중량%가 적절하다.Skin conditioning agents include menthol, betaine, allantoin, licorice extract, aloe vera leaf extract, yeast / mistlet fermented extract, lactobacillus / soybean Fermented extract, yeast / hair root fermented extract, niacinamide (calcium pantothenate), pyridoxine HCl, maltodextrin (maltodextrin) and the like can be used. The content of the skin conditioner is suitably 1 to 10% by weight based on the total weight of the composition.
점증제로는 카보머(carbomer), 덱스트린 등을 사용할 수 있다. 점증제의 함량은 조성물 전체 중량에 대하여 0.01 내지 5 중량%가 적절하다.As the thickener, carbomer, dextrin, etc. may be used. The content of the thickener is suitably 0.01 to 5% by weight based on the total weight of the composition.
pH 조절제로는 트리에탄올아민(triethanolamine) 등을 사용할 수 있다. pH 조절제의 함량은 조성물 전체 중량에 대하여 0.01 내지 5 중량%가 적절하다.As a pH adjuster, triethanolamine, etc. can be used. The content of the pH adjuster is suitably 0.01 to 5% by weight based on the total weight of the composition.
계면활성제로는 피이지-60 하이드로제네이티드 캐스터 오일(PEG-60 hydrogenated caster oil) 등을 사용할 수 있다. 계면활성제의 함량은 조성물 전체 중량에 대하여 0.01 내지 5 중량%가 적절하다.As the surfactant, PIG-60 hydrogenated caster oil may be used. The content of the surfactant is suitably 0.01 to 5% by weight based on the total weight of the composition.
방부제로는 메틸 파라벤(methyl paraben) 등을 사용할 수 있다. 방부제의 함량은 조성물 전체 중량에 대하여 0.01 내지 5 중량%가 적절하다.As a preservative, methyl paraben can be used. The amount of preservative is suitably 0.01 to 5% by weight based on the total weight of the composition.
산화방지제로는 소듐 아스코빌 포스페이트(sodium ascorbyl phosphate), 토코페릴 아세테이트(tocopheryl acetate) 등을 사용할 수 있다. 산화방지제의 함량은 조성물 전체 중량에 대하여 0.01 내지 5 중량%가 적절하다.As antioxidants, sodium ascorbyl phosphate, tocopheryl acetate, and the like can be used. The amount of antioxidant is suitably 0.01 to 5% by weight based on the total weight of the composition.
금속이온 봉쇄제로는 디소듐 이디티에이(disodium EDTA) 등을 사용할 수 있다. 금속이온 봉쇄제의 함량은 조성물 전체 중량에 대하여 0.01 내지 5 중량%가 적절하다.As the metal ion blocking agent, disodium EDTA may be used. The content of the metal ion sequestrant is suitably 0.01 to 5% by weight based on the total weight of the composition.
팽윤제로는 아밀로덱스트린(amylodextrin), 실리카 등을 사용할 수 있다. 팽윤제의 함량은 조성물 전체 중량에 대하여 0.01 내지 5 중량%가 적절하다.Amylodextrin, silica, etc. can be used as a swelling agent. The amount of swelling agent is suitably 0.01 to 5% by weight based on the total weight of the composition.
착색제로는 청색1호 등을 사용할 수 있다. 착색제의 함량은 조성물 전체 중량에 대하여 0.00001 내지 1 중량%가 적절하다.Blue 1 and the like can be used as the colorant. The content of the colorant is suitably 0.00001 to 1% by weight based on the total weight of the composition.
본 발명의 피부 도포용 조성물을 제조하는 방법은 다음과 같다.The method of manufacturing the composition for skin application of the present invention is as follows.
먼저, 정제수, 나이아신 아미드, 아밀로덱스트린, 칼슘 판토테네이트, 말토덱스트린, 소듐 아스코빌 포스페이트, 토코페릴 아세테이트, 피리독신 에이치씨엘, 실리카, 베타인, 감초 추출물, 글루코오스, 덱스트린, 디소듐 이디티에이, 알란토인을 포함하는 A상을 메인 가마에 투입하고 교반한다.First, purified water, niacin amide, amylodextrin, calcium pantothenate, maltodextrin, sodium ascorbyl phosphate, tocopheryl acetate, pyridoxine HCI, silica, betaine, licorice extract, glucose, dextrin, disodium ideti, allantoin Phase A containing a into a main kiln and stirred.
다음, A상의 용해를 확인한 후, 미리 풀어둔 정제수와 카보머를 포함하는 B상을 메인 가마에 투입하고 교반한다.Next, after confirming dissolution of the A phase, the B phase containing purified water and carbomer previously released is introduced into the main kiln and stirred.
다음, B상의 완전 용해를 확인한 후, 미리 희석시켜 둔 정제수와 트리에탄올아민을 포함하는 C상을 메인 가마에 투입하고 교반한다.Next, after confirming complete dissolution of phase B, the phase C containing purified water and triethanolamine previously diluted is added to the main kiln and stirred.
다음, 완전 용해를 확인한 후, 별도 용기에 실온의 정제수와 견운모 파우더를 포함하는 D상을 투입하고 교반하여 완전 분산시킨 후, 이를 바로 메인 가마에 교반하면서 투입한다. 이때, D상을 방치하면 가라앉아 덩어리지므로, 분산 후 바로 투입하는 것이 바람직하다. 견운모 파우더는 나노 크기인 것이 바람직한데, 나노 크기의 견운모 파우더는 통상의 나노 제조기술을 이용하여 만들 수 있다.Next, after confirming complete dissolution, the D phase containing purified water at room temperature and mica powder in a separate container was added and stirred to disperse completely, and then immediately added to the main kiln while stirring. At this time, if the D phase is left to stand, it sinks and agglomerates, so it is preferable to immediately add the dispersion. The biotite powder is preferably nanosized, and the nanosized biotite powder can be made using conventional nanofabrication techniques.
다음, 메인가마의 분산을 확인 후, 미리 가용화시킨 프로필렌 글리콜, 멘톨, 메틸 파라벤, 피이지-60 하이드로제네이티드 캐스터 오일을 포함하는 E상을 투입한 후, 에탄올을 포함하는 F상으로 헹구어 마저 투입한다.Next, after confirming the dispersion of the main kiln, E phase containing pre-solubilized propylene glycol, menthol, methyl paraben and Fiji-60 hydrogenated castor oil was added, followed by rinsing with F phase containing ethanol. do.
다음, 용해를 확인한 후, 착색제를 포함하는 G상과, 알로에 베라 잎 추출물, 효모/겨우살이 발효 추출물, 락토바실러스/콩 발효 추출물, 효모/모근 발효 추출물, 부틸렌 글리콜, 글리세린을 포함하는 H상을 순서대로 투입하고 교반한다.Next, after confirming dissolution, the G phase containing the colorant, the H phase containing aloe vera leaf extract, yeast / mistletoe fermentation extract, lactobacillus / soybean fermentation extract, yeast / hair root fermentation extract, butylene glycol, glycerin Put in order and stir.
마지막으로, 성상을 확인한 후 제조된 반제품의 품질을 검사한다.Finally, the quality of the manufactured semi-finished product is checked after the appearance is confirmed.
본 발명에 따른 조성물은 과도한 운동이나 등산, 스트레스로 인해 뭉친 근육을 풀어주는 마사지용 크림으로 바람직하게 사용될 수 있다.The composition according to the present invention may be preferably used as a massage cream for releasing clumped muscles due to excessive exercise, hiking, or stress.
본 발명의 조성물은 나노 게르마늄의 멘톨 작용과 천연 유항수를 정제해 개발한 제품으로, 피부의 이상 부위에 도포할 경우 깊숙이 침투해 뭉친 근육이나 혈액순환을 돕는다. 또한, 나노기술로 제조된 게르마늄을 함유하여 빠른 시간에 피부 깊숙이 침투하여 지속적인 효과를 느낄 수 있다. 또한, 게르마늄이 함유되어 물리치료실에서 마사지 및 초음파할 때 보조제로서 사용될 수 있다. 또한, 게르마늄의 반도체 성질을 이용하여 우리 몸의 근육과 관절 등에 잘못된 전위에서 나타나는 이상 현상을 정상으로 회복시켜 주는데 도움이 된다. 또한, 빠른 흡수작용으로 끈적임, 도포 흔적과 냄새가 전혀 없다. 또한, 나노 게르마늄과 멘톨의 작용으로 뭉친 근육이나 혈액 순환을 돕는다. 또한, 스포츠 선수들의 과도한 운동으로 인한 근육 뭉침이나 피로를 풀어주는데 도움을 준다. 또한, 피로에 지친 근육관리를 위해 어깨, 허벅지 등의 부위에 가볍게 마사지하면 효과적이다. 또한, 통증 재활병원에서 임상실험과 초음파 및 마사지할 때 사용될 수 있다.The composition of the present invention is a product developed by refining the menthol action of natural germanium and natural bran water, and when applied to an abnormal site of the skin, deeply penetrates to help clumped muscles or blood circulation. In addition, it contains germanium, manufactured by nanotechnology, and penetrates deep into the skin in a short time to feel a lasting effect. In addition, germanium may be contained and used as an adjuvant when massaging and sonicating in a physiotherapy room. In addition, the semiconductor properties of germanium can be used to help restore abnormalities caused by incorrect potentials in the muscles and joints of the body. In addition, there is no stickiness, traces of application and no smell due to fast absorption. In addition, the action of nano germanium and menthol to help clump muscle and blood circulation. It also helps relieve muscle clumping and fatigue caused by excessive exercise by sports athletes. In addition, it is effective to massage lightly on the shoulders, thighs, etc. for tired muscle management. It can also be used in clinical trials and ultrasound and massage in pain rehabilitation hospital.
본 발명에 따른 피부 도포용 조성물의 사용방법을 간략히 설명하면, 바디 관리시에는 충분한 양을 피부에 도포하여 골고루 바르고 가볍게 마사지해준다. 피로에 지친 근육관리를 위해 사용할 경우에는 어깨나 허벅지, 이상 부위에 바른 후 가볍게 마사지한다. 발 관리와 경락 마사지에는 부위에 적당량을 바르고 마사지해준다. 고주파, 초음파, 저주파기 사용시 윤활제로 사용한다. 핫팩 또는 아이스팩 사용시 먼저 도포한 후 사용하면 더욱 큰 효과를 볼 수 있다.Briefly describing how to use the composition for applying the skin according to the present invention, during body care, a sufficient amount is applied to the skin to evenly and lightly massage. If you use it to manage tired muscles, lightly massage it on your shoulders, thighs, or anomalies. For foot care and meridian massage, apply an appropriate amount to the area and massage. Used as lubricant when using high frequency, ultrasonic wave or low frequency. When using hot pack or ice pack, apply it first and then use it.
[실시예][Example]
표 1의 조성을 갖는 피부 도포용 조성물을 제조하였다.The skin coating composition which has a composition of Table 1 was prepared.
표 2를 참조하여 구체적인 제조방법을 설명하면, 먼저 A상을 메인 가마에 투입하고 교반하였다. A상의 용해를 확인한 후, 미리 풀어둔 B상을 투입하고 교반하였다. B상의 완전 용해를 확인한 후, 미리 희석시켜 둔 C상을 투입하고 교반하였다. 완전 용해를 확인한 후, 별도 용기에 D상의 실온수를 넣고 견운모 파우더를 투입 교반하여 완전 분산을 확인한 후, 바로 메인가마에 교반하면서 투입하였다. 메인가마의 분산을 확인한 후, 미리 가용화시킨 E상을 투입한 후 F상으로 헹구어 마저 투입하였다. 용해를 확인한 후 G상과 H상을 순서대로 투입 교반하였다. 이와 같이 제조된 반제품을 품질 검사를 거쳐 튜브에 충전한 후 포장하여 완제품을 제조하였다.Referring to Table 2, a specific manufacturing method is described. First, phase A is added to the main kiln and stirred. After confirming dissolution of the A phase, the previously released B phase was added and stirred. After confirming complete dissolution of the B phase, the previously diluted C phase was added and stirred. After confirming complete dissolution, the room temperature water of the D phase was placed in a separate container, followed by stirring and mixing the villi powder, and confirming complete dispersion, and immediately adding the mixture to the main kiln while stirring. After confirming the dispersion of the main kiln, the solubilized E phase was added, followed by rinsing with the F phase. After confirming the dissolution, the G and H phases were added and stirred in order. The semi-finished product thus prepared was filled in a tube through quality inspection and then packaged to produce a finished product.
[시험예][Test Example]
1. 혈류속도에 미치는 영향1. Effect on Blood Flow Rate
실시예의 조성물을 바르기 전과 후에 우측 요골 동맥에서 혈류속도의 변화를 측정하였다. 측정 전후에 변화된 상황은 전혀 없으며, 측정에 영향을 주는 어떠한 요인도 배제하였다. 혈류속도는 신소재 환경연구소에 의뢰하여 혈류속도측정기(ES-1000SP II)로 측정하였다. 그 결과는 표 3과 같다.The change in blood flow rate in the right radial artery was measured before and after applying the composition of the example. There was no change in the situation before or after the measurement and any factors affecting the measurement were excluded. Blood flow rate was measured by blood flow rate meter (ES-1000SP II) by requesting new material environmental research institute. The results are shown in Table 3.
표 3에서 확인할 수 있듯이, 평균 혈류속도가 도포 전을 기준으로 약 63% 증가하였다.As can be seen in Table 3, the mean blood flow rate increased about 63% before application.
2. 열화상 측정2. Thermal image measurement
적외선 열화상 장치를 이용하여 실내온도 22℃, 습도 40% 조건에서 시험하였으며, 실시예의 조성물을 바르기 전과 후에 측정대상물에서 방사되는 적외선 방사에너지를 영상과 온도 데이터로 처리하였다. 온도분포가 높은 쪽이 혈액순환이 잘 되는 건강한 상태인데, 측정결과 실시예의 조성물을 바른 후가 바르기 전보다 온도분포가 높게 나와 혈액순환이 잘 이루어짐을 알 수 있었다.The infrared thermal imager was used to test at room temperature of 22 ° C. and 40% humidity. The infrared radiation energy emitted from the measurement object was treated with images and temperature data before and after applying the composition of the example. The higher the temperature distribution, the better the blood circulation, but a healthy state, after the application of the composition of the results showed that the temperature distribution is higher than before the application of the blood circulation was well achieved.
3. 적혈구 변화실험3. Red blood cell change experiment
적혈구 측정은 살아 움직이는 적혈구와 백혈구 등 구성성분의 모양, 크기, 형태를 관찰하여 정상적인 활동 여부를 판단함으로써 현재의 모 상태를 확인하는 상태검사이다. 적혈구 변화실험은 특정 환자의 병명을 알아내기 위한 검사가 아니며, 각 장부의 유기적 연락매체인 혈액의 건전성을 확인하는 검사이다.Erythrocyte measurement is a state test that checks the current parental state by determining the normal activity by observing the shape, size, and shape of constituents such as live red blood cells and white blood cells. The RBC test is not a test to determine the disease name of a particular patient. It is a test to check the health of blood, an organic contact medium of each book.
상온, 일반 상태에서 시험자의 손에서 혈액을 채취한 후 현미경을 통해 적혈구의 상태를 측정하였으며, 실시예의 조성물을 도포하기 전과 도포하고 30분 경과 후의 적혈구를 측정하였다.After collecting blood from the tester's hands at room temperature and normal conditions, the red blood cells were measured under a microscope. The red blood cells were measured before and 30 minutes after applying the composition of the example.
연전 현상(Rouleau formation)은 적혈구가 차곡차곡 쌓여 원통 모양으로 배열되는 현상을 말한다. 적혈구의 점착은 혈액 순환 장애 시에도 볼 수 있는데, 인체에서 이용할 수 있는 산소와 영양물질의 양을 감소시켜 피로와 허약, 소화불량 및 부종의 증상을 보인다. 일반적으로 음주, 흡연, 과로, 스트레스 등이 원인이 되어 적혈구가 뭉쳐 혈액순환이 원활하지 못한 상태가 된다.Rooleau formation refers to a phenomenon in which red blood cells are stacked and arranged in a cylindrical shape. The adhesion of red blood cells can also be seen when blood circulation is impaired, reducing the amount of oxygen and nutrients available to the body, resulting in fatigue, weakness, indigestion and edema. In general, drinking, smoking, overwork, and stress caused by the red blood cells are united in a blood circulation is not smooth.
실시예의 조성물을 도포하기 전에는 연전 현상이 발생하였는데, 도포하고 30분 경과 후에는 이러한 현상이 발생하지 않았다.Before the application of the composition of the example, the jeonjeon phenomenon occurred, 30 minutes after the application did not occur this phenomenon.
4. 완제품 시험4. Finished product test
표 4와 같이 완제품 시험을 실시하였으며, 그 결과 시험기준을 모두 충족하였다.The finished product test was performed as shown in Table 4, and as a result, all the test criteria were met.
5. 원적외선 방사율 및 방사에너지, 음이온5. Far Infrared Emissivity, Radiation Energy, Anion
표 5는 한국원적외선응용평가연구원에 의뢰한 원적외선 방사율 및 방사에너지, 음이온 측정결과이다. 원적외선 방사율 및 방사에너지는 KFIA-FI-1005에 의거하여 FT-IR Spectrometer를 이용한 흑체 대비 측정결과이다. 음이온은 KFIA-FI-1042에 의거하여 전하입자 측정장치를 이용하여 실내온도 20℃, 습도 34%, 대기 중 음이온수 106/cc 조건에서 시험하였으며, 측정 대상물에서 방출되는 음이온을 측정하여 단위 체적당 이온수로 표시한 결과이다.Table 5 shows the results of measurement of far-infrared emissivity, radiation energy and anion requested by Korea Far Infrared Application Evaluation Institute. Far-infrared emissivity and radiant energy are the result of black body comparison using FT-IR Spectrometer based on KFIA-FI-1005. Negative ions were tested at room temperature 20 ℃, humidity 34%, and anion water 106 / cc condition using charge particle measuring device in accordance with KFIA-FI-1042. The result is shown in deionized water.
6. 탈취시험6. Deodorization test
표 6은 한국원적외선응용평가연구원에 의뢰한 탈취시험 결과이다. 시험방법은 KFIA-FI-1004이었고, 시험가스는 암모니아를 사용하였으며, 가스농도는 가스 검지관으로 측정하였다.Table 6 shows the results of the deodorization test commissioned by Korea Far Infrared Application Evaluation Institute. The test method was KFIA-FI-1004, the test gas was ammonia, and the gas concentration was measured by a gas detector tube.
Claims (5)
정제수와 카보머를 포함하는 B상;
정제수와 트리에탄올아민을 포함하는 C상;
정제수와, 게르마늄을 포함하고 나노 크기로 이루어진 견운모를 포함하는 D상;
프로필렌 글리콜, 멘톨, 메틸 파라벤, 피이지-60 하이드로제네이티드 캐스터 오일을 포함하는 E상;
에탄올을 포함하는 F상;
착색제를 포함하는 G상; 및
알로에 베라 잎 추출물, 효모/겨우살이 발효 추출물, 락토바실러스/콩 발효 추출물, 효모/모근 발효 추출물, 부틸렌 글리콜, 글리세린을 포함하는 H상을 순서대로 혼합하여 만든 피부 도포용 조성물.Contains purified water, niacin amide, amylodextrin, calcium pantothenate, maltodextrin, sodium ascorbyl phosphate, tocopheryl acetate, pyridoxine HCI, silica, betaine, licorice extract, glucose, dextrin, disodium ideti, allantoin A phase;
Phase B containing purified water and carbomer;
Phase C comprising purified water and triethanolamine;
Phase D, including purified water, and germanium, nanoscale biotite;
Phase E including propylene glycol, menthol, methyl paraben, Fiji-60 hydrogenated castor oil;
Phase F including ethanol;
G phase containing a coloring agent; And
Composition for skin application made by mixing H phase containing aloe vera leaf extract, yeast / mistletoe fermentation extract, lactobacillus / soybean fermentation extract, yeast / hair root fermentation extract, butylene glycol, glycerin in order.
A상의 용해를 확인한 후, 미리 풀어둔 정제수와 카보머를 포함하는 B상을 메인 가마에 투입하고 교반하는 단계;
B상의 완전 용해를 확인한 후, 미리 희석시켜 둔 정제수와 트리에탄올아민을 포함하는 C상을 메인 가마에 투입하고 교반하는 단계;
완전 용해를 확인한 후, 별도 용기에 실온의 정제수와 견운모 파우더를 포함하는 D상을 투입하고 교반하여 완전 분산시킨 후, 이를 바로 메인 가마에 교반하면서 투입하는 단계;
메인가마의 분산을 확인 후, 미리 가용화시킨 프로필렌 글리콜, 멘톨, 메틸 파라벤, 피이지-60 하이드로제네이티드 캐스터 오일을 포함하는 E상을 투입한 후, 에탄올을 포함하는 F상으로 헹구어 마저 투입하는 단계; 및
용해를 확인한 후, 착색제를 포함하는 G상과, 알로에 베라 잎 추출물, 효모/겨우살이 발효 추출물, 락토바실러스/콩 발효 추출물, 효모/모근 발효 추출물, 부틸렌 글리콜, 글리세린을 포함하는 H상을 순서대로 투입하고 교반하는 단계를 포함하는 피부 도포용 조성물의 제조방법.Contains purified water, niacin amide, amylodextrin, calcium pantothenate, maltodextrin, sodium ascorbyl phosphate, tocopheryl acetate, pyridoxine HCI, silica, betaine, licorice extract, glucose, dextrin, disodium ideti, allantoin Adding phase A into the main kiln and stirring;
After confirming the dissolution of phase A, adding the purified water and carbomer phase B previously released into the main kiln and stirring;
After confirming complete dissolution of phase B, adding phase C containing purified water and triethanolamine previously diluted to the main kiln and stirring;
After confirming complete dissolution, the phase D containing purified water and mica powder at room temperature in a separate container and stirred to completely disperse, and then immediately adding it to the main kiln while stirring;
After confirming the dispersion of the main kiln, injecting the E phase containing propylene glycol, menthol, methyl paraben, PIG-60 hydrogenated castor oil solubilized in advance, and then rinsing with an F phase containing ethanol and then adding ; And
After confirming the dissolution, the G phase containing the colorant and the H phase including the aloe vera leaf extract, the yeast / muslet fermented extract, the Lactobacillus / soybean fermented extract, the yeast / hair root fermented extract, the butylene glycol, and glycerin in order Method of producing a composition for applying the skin comprising the step of adding and stirring.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110036554A KR101303131B1 (en) | 2011-04-20 | 2011-04-20 | Composition for applying on skin containing sericite |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110036554A KR101303131B1 (en) | 2011-04-20 | 2011-04-20 | Composition for applying on skin containing sericite |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20120118908A KR20120118908A (en) | 2012-10-30 |
KR101303131B1 true KR101303131B1 (en) | 2013-09-25 |
Family
ID=47286242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020110036554A KR101303131B1 (en) | 2011-04-20 | 2011-04-20 | Composition for applying on skin containing sericite |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101303131B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101713900B1 (en) * | 2014-04-24 | 2017-03-09 | 주식회사 엘지생활건강 | Cosmetic composition comprising high-content of calcium pantothenate and manufacturing method thereof |
KR102233370B1 (en) * | 2020-09-16 | 2021-03-30 | 주식회사 다나제약 | Method of manufacture of kennel extract, kennel solvent extract manufactured by the above method, and method of manufacture of natural mineral ion water using the kennel solvent extract |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050050337A (en) * | 2003-11-25 | 2005-05-31 | (주)언일전자 | Natural germanium for packing |
-
2011
- 2011-04-20 KR KR1020110036554A patent/KR101303131B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050050337A (en) * | 2003-11-25 | 2005-05-31 | (주)언일전자 | Natural germanium for packing |
Also Published As
Publication number | Publication date |
---|---|
KR20120118908A (en) | 2012-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101897838B (en) | External hot applied mud moxibustion for human body and application method thereof | |
CN103479775B (en) | Scraping liniment and preparation method thereof | |
CN105769654A (en) | Anti-sensitivity skin-care composition and application thereof to cosmetics | |
CN106421695A (en) | Traditional Chinese medicine composition for eye care | |
CN105434405A (en) | Eye-protection mask, and preparation method thereof | |
CN103446365B (en) | Ointment for treating myopia and preparation method thereof | |
CN102526361A (en) | Far-infrared thermo-magnetic moxibustion therapeutic paste protective agent and magnetic moxibustion therapeutic paste thereof | |
KR20180083719A (en) | A aromatic composition having anti-stress and fatigue relaxing, and a cosmetic composition containing the same | |
CN108379411A (en) | The Chinese medicine bathing instant granular of improvement sleep quality and preparation and application method | |
KR101303131B1 (en) | Composition for applying on skin containing sericite | |
WO2020140338A1 (en) | Pain relieving compound essential oil and preparation method and application thereof | |
CN109568427A (en) | A kind of activating microcirculation and removing stasis medicinal, the traditional Chinese medicine extraction preparation soft muscle dissipating bind, alleviated muscular strain, improve debilitating pain | |
CN104940124A (en) | Traditional Chinese medicine composition and preparation method and usage thereof and facial mask containing composition | |
CN102008698A (en) | Traditional Chinese medicine composition and preparation for curing dysmenorrhea | |
CN105497537A (en) | Medicine composition with skin whitening and tendering functions and preparing method thereof | |
KR102413394B1 (en) | Composition for removing bruises and skin external materials comprising the same | |
CN104095797B (en) | A kind of Herba Blumeae Balsamiferae compositions of speckle dispelling and application thereof | |
WO2012023179A1 (en) | Long-acting dermatological antipruritic agent | |
CN213406932U (en) | Nano thermal inductance massage plaster body, plaster and plaster | |
CN1660264A (en) | Combination of Chinese traditional for feet bath and preparation method | |
WO2015125963A1 (en) | Therapeutic oil containing natural ore | |
CN113576987A (en) | Massage gel applied to wave instrument and preparation method thereof | |
CN105106085A (en) | Chinese medicinal herb sunscreen cream containing attapulgite | |
CN104771328A (en) | Carbonate spring tablet and preparation method thereof | |
CN101721486A (en) | Eye guard for treating insomnia and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20160819 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20170803 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20180730 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20190722 Year of fee payment: 7 |
|
R401 | Registration of restoration | ||
R401 | Registration of restoration |